Concordance of cancer drug therapy information derived from routinely collected hospital admissions data and the Systemic Anti-Cancer Therapy (SACT) dataset, for older women diagnosed with early invasive breast cancer in England

Gannon, Melissa; Park, Min Hae; Miller, Katie; Horgan, Kieran; Clements, Karen; Medina, Jibby; Cromwell, David

doi:10.1016/j.canep.2023.102337

Cancer Epidemiology

2023

DOI: 10.1016/j.canep.2023.102337

|View full text |Cite

Concordance of cancer drug therapy information derived from routinely collected hospital admissions data and the Systemic Anti-Cancer Therapy (SACT) dataset, for older women diagnosed with early invasive breast cancer in England

Melissa Gannon

Min Hae Park

Katie Miller

et al.

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...

Citation Types

Supporting

Mentioning

Contrasting

Year Published

2023

2024

Publication Types

Select...

Article2

Relationship

Self Cite1

Independent1

Authors

Journals

Cited by 2 publications

References 19 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

Survival following adjuvant trastuzumab-based treatment among older patients with HER2-positive early invasive breast cancer: A national population-based cohort study using routine data

Gannon,

Dodwell,

Miller

et al. 2024

European Journal of Cancer

View full text Add to dashboard Cite

Survival following adjuvant trastuzumab-based treatment among older patients with HER2-positive early invasive breast cancer: A national population-based cohort study using routine data

Gannon,

Dodwell,

Miller

et al. 2024

European Journal of Cancer

View full text Add to dashboard Cite

Treatment-related acute toxicity with adjuvant systemic treatment among patients with HER2-positive early invasive breast cancer: a national population-based cohort study

Gannon,

Dodwell,

Miller

et al. 2023

bmjonc

Self Cite

View full text Add to dashboard Cite

ObjectiveAlthough adjuvant trastuzumab-based treatment (TBT) improves survival for patients with HER2-positive early invasive breast cancer (EIBC), risk of toxicity grows as patient age increases. We examined use of TBT and associated severe acute toxicity event (SATE) rates to understand the real-world impact.Methods and analysisWomen (50+ years), newly diagnosed with HER2-positive EIBC in England, 2014–2019, were identified from Cancer Registry data, linked to the Systemic Anti-Cancer Therapy dataset for TBT information. SATEs were measured using hospital administrative data. Statistical models were developed to identify potential predictors of SATE.ResultsAmong 5087 women who received trastuzumab, with median duration 11.7 months, 47.4% (95% CI 46.0% to 48.7%) completed treatment. Women aged 70+ years made up 20.2% of patients aged 50+ who received adjuvant TBT in routine care, compared with 5% of women aged 50+ across trials. 32.8% (95% CI 31.5% to 34.1%) had a record of any SATE. 6.8% (95% CI 6.1% to 7.5%) had a cardiovascular SATE. Congestive cardiac failure rate was 0.5% (95% CI 0.3% to 0.7%). High deprivation, anthracycline use, increasing frailty were associated with increased odds of any SATE. Older age, sequential chemotherapy, history of myocardial infarction/chronic pulmonary disorder/liver disease were associated with increased odds of cardiovascular SATE. Among two-thirds of women not eligible for trial cohorts SATE rates were lower than for trial-eligible patients, explained by baseline differences in patients.ConclusionEvidence of treatment-related SATE among patients treated in routine care is needed to inform treatment decisions and counsel older patients. This study provides information on SATE rates for adjuvant TBT, and common types, overall and by age for such discussions.

show abstract

scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.

Contact Info

customersupport@researchsolutions.com

10624 S. Eastern Ave., Ste. A-614

Henderson, NV 89052, USA

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Blog Terms and Conditions API Terms Privacy Policy Contact Cookie Preferences Do Not Sell or Share My Personal Information

Made with 💙 for researchers

Part of the Research Solutions Family.

Concordance of cancer drug therapy information derived from routinely collected hospital admissions data and the Systemic Anti-Cancer Therapy (SACT) dataset, for older women diagnosed with early invasive breast cancer in England

Cited by 2 publications

References 19 publications

Survival following adjuvant trastuzumab-based treatment among older patients with HER2-positive early invasive breast cancer: A national population-based cohort study using routine data

Survival following adjuvant trastuzumab-based treatment among older patients with HER2-positive early invasive breast cancer: A national population-based cohort study using routine data

Treatment-related acute toxicity with adjuvant systemic treatment among patients with HER2-positive early invasive breast cancer: a national population-based cohort study

Contact Info

Product

Resources

About